Cargando…

PPI adverse drugs reactions: a retrospective study

Proton pump inhibitors (PPIs) are drugs capable of blocking the gastric pump H,K-ATPase in order to inhibit gastric acid secretion. Omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole belong to PPIs category. Although PPIs have a good safety profile, allergic reactions to these mole...

Descripción completa

Detalles Bibliográficos
Autores principales: Casciaro, Marco, Navarra, Michele, Inferrera, Giuseppina, Liotta, Marta, Gangemi, Sebastiano, Minciullo, Paola Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337765/
https://www.ncbi.nlm.nih.gov/pubmed/30675130
http://dx.doi.org/10.1186/s12948-019-0104-4
_version_ 1783388325952880640
author Casciaro, Marco
Navarra, Michele
Inferrera, Giuseppina
Liotta, Marta
Gangemi, Sebastiano
Minciullo, Paola Lucia
author_facet Casciaro, Marco
Navarra, Michele
Inferrera, Giuseppina
Liotta, Marta
Gangemi, Sebastiano
Minciullo, Paola Lucia
author_sort Casciaro, Marco
collection PubMed
description Proton pump inhibitors (PPIs) are drugs capable of blocking the gastric pump H,K-ATPase in order to inhibit gastric acid secretion. Omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole belong to PPIs category. Although PPIs have a good safety profile, allergic reactions to these molecules can occur. The real rate of hypersensitive reactions to PPIs is unknown. The aim of this retrospective study is to evaluate the rate of hypersensitive reactions to PPIs in patients admitted to our Unit between 2008 and 2013 with a history of drug hypersensitivity. From a database of 1229 patients (921 women, 308 men) with adverse drug reaction we extrapolated the data about PPI reactions. Twelve patients (10 female, 2 men) had a positive history for hypersensitive reaction to PPI. Pantoprazole was the most frequently PPI involved. Based on patient personal history in some cases we performed an oral challenge test for an alternative anti-acid drug and none of them had adverse reactions. According to our experience and according to the literature and pharmacovigilance reports, ADR caused by PPIs are ever increasing. Adverse reactions to these drugs are still under-reported; however, considering the frequency of their prescription worldwide, the risk of severe allergic events is low. Further studies are needed to provide clearer data on the real incidence and prevalence about this matter. This should be useful to help physician in choosing the molecule to prescribe and, in case of hypersensitivity, the alternative molecule to test, also considering the possible cross-reactivity.
format Online
Article
Text
id pubmed-6337765
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63377652019-01-23 PPI adverse drugs reactions: a retrospective study Casciaro, Marco Navarra, Michele Inferrera, Giuseppina Liotta, Marta Gangemi, Sebastiano Minciullo, Paola Lucia Clin Mol Allergy Research Proton pump inhibitors (PPIs) are drugs capable of blocking the gastric pump H,K-ATPase in order to inhibit gastric acid secretion. Omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole belong to PPIs category. Although PPIs have a good safety profile, allergic reactions to these molecules can occur. The real rate of hypersensitive reactions to PPIs is unknown. The aim of this retrospective study is to evaluate the rate of hypersensitive reactions to PPIs in patients admitted to our Unit between 2008 and 2013 with a history of drug hypersensitivity. From a database of 1229 patients (921 women, 308 men) with adverse drug reaction we extrapolated the data about PPI reactions. Twelve patients (10 female, 2 men) had a positive history for hypersensitive reaction to PPI. Pantoprazole was the most frequently PPI involved. Based on patient personal history in some cases we performed an oral challenge test for an alternative anti-acid drug and none of them had adverse reactions. According to our experience and according to the literature and pharmacovigilance reports, ADR caused by PPIs are ever increasing. Adverse reactions to these drugs are still under-reported; however, considering the frequency of their prescription worldwide, the risk of severe allergic events is low. Further studies are needed to provide clearer data on the real incidence and prevalence about this matter. This should be useful to help physician in choosing the molecule to prescribe and, in case of hypersensitivity, the alternative molecule to test, also considering the possible cross-reactivity. BioMed Central 2019-01-18 /pmc/articles/PMC6337765/ /pubmed/30675130 http://dx.doi.org/10.1186/s12948-019-0104-4 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Casciaro, Marco
Navarra, Michele
Inferrera, Giuseppina
Liotta, Marta
Gangemi, Sebastiano
Minciullo, Paola Lucia
PPI adverse drugs reactions: a retrospective study
title PPI adverse drugs reactions: a retrospective study
title_full PPI adverse drugs reactions: a retrospective study
title_fullStr PPI adverse drugs reactions: a retrospective study
title_full_unstemmed PPI adverse drugs reactions: a retrospective study
title_short PPI adverse drugs reactions: a retrospective study
title_sort ppi adverse drugs reactions: a retrospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337765/
https://www.ncbi.nlm.nih.gov/pubmed/30675130
http://dx.doi.org/10.1186/s12948-019-0104-4
work_keys_str_mv AT casciaromarco ppiadversedrugsreactionsaretrospectivestudy
AT navarramichele ppiadversedrugsreactionsaretrospectivestudy
AT inferreragiuseppina ppiadversedrugsreactionsaretrospectivestudy
AT liottamarta ppiadversedrugsreactionsaretrospectivestudy
AT gangemisebastiano ppiadversedrugsreactionsaretrospectivestudy
AT minciullopaolalucia ppiadversedrugsreactionsaretrospectivestudy